登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《LANCET，4月3日，Baricitinib for COVID-19: a suitable treatment? – Authors' reply》

  • 来源专题：COVID-19科研动态监测
  • 编译者： xuwenwhlib
  • 发布时间：2020-04-04

  • Baricitinib for COVID-19: a suitable treatment? – Authors' reply

    Peter J Richardson，Mario Corbellino，Justin Stebbing

    Published:April 03, 2020DOI:https://doi.org/10.1016/S1473-3099(20)30270-X

    We thank Ennio Favalli and colleagues for their Correspondence regarding our suggestion to use baricitinib for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.1, 2 We also appreciate their recognition that inhibition of numb-associated kinase enzymes could indeed be beneficial in preventing virus infectivity via inhibition of clathrin-mediated endocytosis.

    We welcome the opportunity to more fully explain the possible use of baricitinib in the current pandemic. Indeed, we accept that using a JAK1 and JAK2 inhibitor to treat a viral disease might appear illogical given that the antiviral effects of interferons are largely mediated by the JAK–STAT signalling pathway. However, the administration of pegylated-interferon has not had the beneficial antiviral effects originally hoped for,4 and clinical trials with interferons have yielded inconsistent results, with pathogenic effects of interferons being observed in some viral infections.

  • 原文来源：https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30270-X/fulltext
91浏览量
原文链接
相关报告

  • 《LANCET，4月3日，Baricitinib for COVID-19: a suitable treatment?》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-04-04
    • Baricitinib for COVID-19: a suitable treatment? Ennio G Favalli，Martina Biggioggero，Gabriella Maioli，Roberto Caporali Published:April 03, 2020DOI:https://doi.org/10.1016/S1473-3099(20)30262-0 As rheumatologists used to treating rheumatoid arthritis with Janus kinase (JAK) inhibitors and working in an area (Lombardy, Italy) with a high incidence of coronavirus disease 2019 (COVID-19), we read with great interest the Comment in The Lancet Infectious Diseases by Justin Stebbing and colleagues1 about the potential use of baricitinib for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The described mechanism affecting viral endocytosis mediated by two members of the numb-associated kinase family is one of the many unfamiliar effects of a relatively recent drug class, the real safety profile of which still remains to be definitively clarified. Undoubtedly, the fact that baricitinib can provide this antiviral effect at the approved dose for rheumatoid arthritis therapy is an undeniable advantage over other potential inhibitors of the same pathway.
    43浏览量
    原文链接

  • 《LANCET，3月17日，COVID-19 in pregnant women – Authors' reply》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-18
    • COVID-19 in pregnant women – Authors' reply David Baud Eric Giannoni Léo Pomar Xiaolong Qi Karin Nielsen-Saines Didier Musso et al. Show all authors Published:March 17, 2020DOI:https://doi.org/10.1016/S1473-3099(20)30192-4 We are grateful for the concerns of Manuel Schmidt and colleagues about our previous guidelines1 for pregnant women with suspected severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. At the time we developed the algorithm (February, 2020), there were no data regarding potential vertical transmission from infected mothers and outcomes in newborns. To date, there has been no evidence of vertical transmission of coronavirus disease 2019 (COVID-19) based on two small clinical series.2, 3 According to WHO, delayed umbilical cord clamping is highly unlikely to increase the risk of transmitting pathogens from the mother to the fetus even in the case of maternal infection.4 Because the vernix caseosa contains antimicrobial peptides, we recommend leaving it in place until 24 h after birth.5 New data examining neonates from infected mothers could be reassuring, but transmission after birth via contact with infectious respiratory secretions is still a concern, and physical separation of mother from child should be considered. Separation is a standard practice in pulmonary tuberculosis and is discussed in cases of maternal influenza infection.6 Therefore, separation of the mother and her newborn baby should be individually discussed by an interdisciplinary team, considering local facilities and risk factors for adverse neonatal outcomes, such as prematurity and fetal distress.
    53浏览量
    原文链接